← brief for 2026-09-10 · People & money

Understanding variation between kidney centres in implementation of tolvaptan in the management of autosomal dominant polycystic kidney disease: a multiple case study

Key takeaways

Kidney centres do not all use tolvaptan the same way. Tolvaptan is a drug that slows cyst growth in polycystic kidney disease, an inherited condition that damages the kidneys over decades. Researchers studied several centres to learn why the drug is offered and managed differently from place to place. This describes how care is delivered, so it shows patterns and possible reasons, not proof that one way of working leads to better health.

Who did this work

Matthew Gittus (University of Sheffield) · James Fotheringham (University of Sheffield) · Albert Ong (University of Sheffield) · Alicia O’Cathain (University of Sheffield)

Source

Paper · OpenAlex, Kidney disease concept sweep (verified C2778653478) · 2026-09-09
https://doi.org/10.1186/s43058-026-01087-7